Bristol-myers Squibb Compnay

Other

Dalton King

John E Macor

Richard Eric Olson

Ivar M McDonald

Christiana I Iwuagwu

F Christopher Zusi

James H Cook, Ii

Nenghui Wang

Raymond A Firestone

Ronald J Mattson

Zhaoxing Meng

Robert A Mate

Piyasena Hewawasam

John E Starrett, Jr

Jayakumar Sankara Warrier

Lawrence R Marcin

Haiquan Fang

Srinivasan Thangathirupathy

Matthew D Hill

Jonathan L Ditta

Pamela A Trail

Derek John Denhart

Imadul Islam

Jeffrey A Deskus

Gene Michael Dubowchik

Jianliang Shi

John D Catt

Lorin A Thompson, Iii

Charles P Sloan

Mendi A Higgins

James R Epperson

George N Karageorge

Rex Denton

Nicholas J Lodge

Li-Quang Sun

Kimberley A Lentz

Lorin A Thompson Iii

James H Cook Ii

James H Ii Cook

Christopher F Zusi

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. 

Selective NR2B antagonists

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system. 

The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands

The disclosure generally relates to compounds of the following formula, including their salts, as well as compositions and methods of using the compounds. The compounds are prodrugs for ligands, agonists, and partial agonists for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Aza-bicyclic amine N-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs

Quinuclidine compounds as &#x3b1;-7 nicotinic acetylcholine receptor ligands

The disclosure provides compounds of formula I, including Ia, Ib, Ic, or Id, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic &#x3b1;7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders. 

Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands

Disclosed are compounds, pharmaceutical compositions containing the compounds, methods for using the compounds and processes for making the compounds. More specifically, the disclosure relates to alpha-(N-benzenesulfonamido)cycloalkyl compounds that may inhibit one or both of: (i) the functioning of a &#x3b3;-secretase enzyme; or (ii) the production of &#x3b2;-amyloid. Such compounds may be beneficial in the treatment of Alzheimer's disease and other conditions. Representative compounds have the following formula I: wherein: A, R, and Rare described herein.

Alpha-(N-benzenesulfonamido)cycloalkyl derivatives

Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts or solvates thereof and pharmaceutically acceptable formulations comprising said compounds useful for the treatment of premature ejaculation, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder, post-traumatic stress disorder and substance abuse disorders.

Compounds for the treatment of premature ejaculation

Cyclopentyl indole derivatives

Cyclopropylindole derivatives as selective serotonin reuptake inhibitors

Conjugates containing a targeting ligand, such as an antibody, a therapeutically active drug and a branched peptide linker. The branched peptide linker contains two or more amino acid moieties that provide an enzyme cleavage site. The number of drugs capable of being bonded to the branched linkers varies by a factor of two for each generation of branching.

Branched peptide linkers

Thiophenyl triazol-3-one derivatives as smooth muscle relaxants

Branched hydrazone linkers for linking a targeting ligand such as an antibody to a therapeutically active drug. The point of branching is at a polyvalent atom and the number of drugs increases by a factor of two for each generation of branching. A preferred drug is doxorubicin.

Branched hydrazone linkers

Growing community of inventors

Hamden, CT, United States of America

Dalton King